ATRC
AtriCure, Inc.
ATRC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ATRC overall, supported by stronger valuation and stronger fundamentals.
ATRC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
ATRC's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATRC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 37x | $11.06 | -80% |
| Fair | 61x | $18.23 | -67% |
| Current | 187x | $55.98 | — |
| Expensive | 203x | $60.96 | +8.9% |
| Forward | 211x | $55.98 | — |
Historical ranges are pointers, not guarantees.
ATRC's PE is in its expensive range at 187x. On analysts' estimates for next year's earnings, today's price would be 211x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ATRC in the historical PE scenario, which offers more potential upside but is not a forecast.
ATRC Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ATRC to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ATRC on the outlook, with more favorable valuation expectations.
ATRC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.26 | -12% |
| Q3 2026 | $0.30 | +$0.91 |
| Q2 2026 | $0.21 | +$0.98 |
| Q1 2026 | -$0.10 | +$0.71 |
| Q4 2025 | -$0.24 | +$0.71 |
| Q3 2025 | -$0.61 | +$0.22 |
| Q2 2025 | -$0.77 | +$0.09 |
| Q1 2025 | -$0.81 | -$0.01 |
| Q4 2024 | -$0.95 | -$0.29 |
ATRC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ATRC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $154.5M | +15% |
| Q2 2026 | $153.6M | +13% |
| Q1 2026 | $141.2M | +14% |
| Q4 2025 | $140.5M | +13% |
| Q3 2025 | $134.3M | +16% |
| Q2 2025 | $136.1M | +17% |
| Q1 2025 | $123.6M | +14% |
| Q4 2024 | $124.3M | +17% |
ATRC's revenue has grown year over year for 23 quarters in a row: $154M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.8% | +2.7 points |
| Q2 2026 | 6.3% | +11 points |
| Q1 2026 | 0.4% | +5.2 points |
| Q4 2025 | 1.8% | +14 points |
| Q3 2025 | 0.1% | +6.5 points |
| Q2 2025 | -4.5% | +1.6 points |
| Q1 2025 | -4.8% | +5.2 points |
| Q4 2024 | -12% | -3.5 points |
ATRC's operating margin was 2.8% last quarter, up 2.7 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ATRC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ATRC on profitability, with a higher operating margin.
ATRC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.9M | -0.7% |
| Q2 2026 | $18.4M | -2.8% |
| Q1 2026 | -$7.8M | +$5.4M |
| Q4 2025 | $18.4M | +486% |
| Q3 2025 | $24.1M | +47% |
| Q2 2025 | $19M | +279% |
| Q1 2025 | -$13.2M | +$10.6M |
| Q4 2024 | $3.1M | +153% |
ATRC generated $53M in free cash flow over the past year, up 60% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ATRC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +963K shares |
| 1 year | +4% | +1.9M shares |
| 3 years | +7.4% | +3.4M shares |
| 5 years | +8.1% | +3.7M shares |
| Available history | +33% | +12.2M shares |
ATRC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ATRC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.3x | Net Cash |
| Q2 2026 | -3.2x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -9.5x | Net Cash |
| Q2 2022 | 0.1x | Very low |
| Q1 2022 | 0.5x | Very low |
| Q4 2021 | 0.3x | Very low |
| Q3 2021 | 0.3x | Very low |
ATRC has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ATRC on leverage, with a lower net debt burden relative to earnings.
ATRC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.5 | Neutral |
| Stochastic | 75.6 | Neutral |
ATRC's weekly RSI is 67 (neutral) and its Stochastic is 76 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ATRC PE vs Healthcare Sector
| Metric | ATRC | Sector median | Relative |
|---|---|---|---|
| PE | 187x | 26x | 622% above |
| PE % | 79 | 29 | 50 pts above |
ATRC is trading at 187x earnings, a 622% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ATRC on valuation relative to its sector.
ATRC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.5 | 2.7% below |
| 20 week MA | $49.1 | 14% above |
| 50 week MA | $39.3 | 43% above |
| 100 week MA | $36.8 | 52% above |
| 200 week MA | $36.3 | 54% above |
ATRC's trend is up, with a small recent dip: it's below only its 8-week average, and 54% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ATRC on trend strength, trading above more of its moving averages.
ATRC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.0 | $57.6 | +80% |
| 2021 | $57.6 | $73.4 | +27% |
| 2022 | $73.4 | $43.7 | -40% |
| 2023 | $43.7 | $35.7 | -18% |
| 2024 | $35.7 | $30.7 | -14% |
| 2025 | $30.7 | $40.3 | +32% |
| 2026 YTD | $40.3 | $56.0 | +39% |
ATRC is up 39% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ATRC on returns for 2026, with the stronger performance.